Ziconotide

Confusion, memory problems, or difficulty concentrating occur in approximately 30-50% of patients. Usually mild and may improve with dose adjustment or time. Monitor cognitive function regularly; dose reduction may be necessary if impairment is significant.

Occurs in 20-40% of patients, particularly during dose titration. Usually transient and improves with continued use. Advise patients to avoid driving or operating machinery until symptoms resolve.

Reported in 15-30% of patients. Often occurs early in treatment and may resolve spontaneously. Antiemetics can be used if needed; slower dose titration may reduce incidence.

Occurs in 10-20% of patients. May be related to intrathecal catheter placement or CSF dynamics. Manage with analgesics; persistent headaches warrant evaluation for catheter malposition or CSF leak.

Blurred vision or diplopia reported in 5-15% of patients. Usually mild and transient. Dose reduction may be necessary if vision changes are significant or persistent.

Aseptic meningitis has been reported in <1% of patients, typically within the first 2 weeks of therapy. Presents with fever, headache, neck stiffness, and elevated CSF white blood cell count. Requires immediate medical evaluation and possible hospitalization. Infectious meningitis is rare but can occur due to pump or catheter infection. Requires antibiotic therapy and possible pump removal.

Includes catheter obstruction, migration, or breakage (1-5% incidence). May present as loss of pain relief or neurological symptoms. Requires imaging and possible surgical intervention.

Pump failure or programming errors can occur. Abrupt cessation of ziconotide delivery can cause severe withdrawal symptoms including rebound pain, fever, and autonomic instability. Requires immediate medical attention and pump interrogation/replacement.

Abrupt discontinuation of ziconotide can cause severe withdrawal characterized by rebound pain, fever, tachycardia, hypertension, rigidity, and altered mental status. Dose must be tapered gradually under medical supervision. Can be life-threatening if not managed appropriately.

Incoordination or gait disturbance reported in 5-10% of patients. Usually dose-related and may improve with dose reduction. Increases fall risk; advise appropriate precautions.

Numbness, tingling, or altered sensation reported in 5-15% of patients. Usually mild and may be difficult to distinguish from underlying neuropathic pain. Monitor for progression.

Surgical site infection or pump pocket infection occurs in 1-3% of patients. Presents with redness, warmth, swelling, drainage, or fever. Requires antibiotic therapy and possible pump removal and reimplantation.

Depression, anxiety, hallucinations, or mood changes reported in 5-10% of patients. More common in patients with history of psychiatric illness. Requires psychiatric evaluation and possible dose adjustment or antipsychotic/antidepressant therapy.

Seizures have been reported rarely (<1% incidence), particularly at higher doses or in patients with predisposing factors. Requires immediate medical evaluation and possible dose reduction or discontinuation.

Blood pressure reduction reported in 5-10% of patients. Monitor blood pressure regularly; dose reduction may be necessary if hypotension is symptomatic.